Testing combined radiation, chemotherapy, and immunotherapy for high-risk sarcoma
Treatments studied
Part of Cancer clinical trials.
This study tests whether giving radiation, chemotherapy, and immunotherapy together can control high-risk soft tissue sarcoma that is hard to remove or may come back after surgery. It may help by attacking cancer in different ways, including boosting the immune system.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed soft tissue sarcoma (STS) that is grade 2 or 3 (faster-growing on pathology)
- Your tumor is larger than 5 cm, or a tumor board says it’s borderline resectable or not safely removable
- Your scans show the cancer is only in the local area (no distant spread to other organs or regions)
- You are 18 to 70, or 70 to 75 with good day-to-day functioning (ECOG 0–1), and you’re expected to live more than 2 years
- Your blood, liver, and kidney tests meet the study minimums
- You can sign the consent form and agree to the treatment plan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 trial tests whether combining radiation with two targeted/immune medicines can shrink or control high-risk soft tissue sarcoma and improve outcomes. It may help patients whose tumors are large, hard to fully remove, or have come back after prior treatment.
This trial tests a combination of immunotherapy (atezolizumab), chemotherapy (doxorubicin), and radiation before and after surgery for people with high-risk soft tissue sarcoma in the arm, leg, or trunk. The goal is to see if this approach can improve outcomes.
This trial tests whether adding chemotherapy before surgery to a combination of immunotherapy (pembrolizumab) and radiation therapy improves outcomes for people with high-risk soft tissue sarcoma (UPS or LPS) in the arm or trunk. It aims to see if this approach can shrink tumors and reduce the chance of cancer returning.
This trial tests a new way of giving radiation therapy (called spatially fractionated radiotherapy) combined with a treatment strategy called PraG (pembrolizumab and granulocyte-macrophage colony-stimulating factor) for people with soft tissue sarcoma that cannot be removed or has spread. The goal is to see if the combination can help shrink or control the cancer.
This trial tests combining anlotinib (a targeted therapy), doxorubicin (chemotherapy), and radiation given before surgery to shrink high-grade soft tissue sarcomas. The goal is to make the tumor easier to remove and improve outcomes.
This trial tests a precision medicine approach by giving targeted therapy before surgery for high-risk soft tissue sarcoma. The goal is to see if matching treatment to your tumor's type can improve outcomes.
Hear when a new High-Risk Localized Soft Tissue Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.